Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Brain metastases developed from HER2 positive and triple negative breast cancer

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.18
Views: 1546

Dr Patricia Steeg - National Cancer Institute, Bethesda, USA

Dr Patricia Steeg speaks to ecancer at SABCS 2018 about how brain metastases can develop from metastatic HER2 positive and triple negative breast cancer.

She reports that a mouse model has been used in order to find a drug that can prevent brain metastases from being developed from these subtypes, with the drug temozolomide showing significant capabilities of prevention.

Dr Steeg explains that a secondary metastases prevention trial has been set up with HER2 positive breast cancer patients who already have signs of brain metastases, with a primary endpoint of no additional brain metastases. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation